AtriCure Inc. (ATRC) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

ATRC scores 63 out of 100, graded C, with the verdict "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars are:

• Fundamental Cash Engine: 10 / 20. Per the RQD rating, this pillar reflects ROIC of -1.9% and an FCF yield of 1.52%. Returns on invested capital are negative, so this is the weakest pillar relative to its weight.
• Whale 13F Flow: 17 / 20. Per the RQD rating, this pillar captures institutional accumulation and options positioning. It is the strongest pillar.
• Insider Conviction: 8 / 20. Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow.
• Macro Regime Fit: 12 / 20. Per the RQD rating, beta is 1.0 and sector sensitivity is factored. A beta of 1.0 implies market-matching sensitivity rather than amplified volatility, but the score indicates only moderate alignment with the current regime.
• Forensic Balance Sheet: 16 / 20. Per the RQD rating, Altman Z is 12.08, Piotroski F is 8/9, and Debt/Equity is 0.13. This is the second-strongest pillar and signals a low-leverage, financially sound balance sheet even while operating results are negative.

Taken together, the investor implication is a trade-off. The balance sheet and institutional positioning provide support, while weak cash returns and insider signals temper the case. The valuation tradeoff is that the stock trades at a market capitalization of $3.18B against negative operating and net margins, so the price relies on expectations of future improvement that the reported figures do not yet confirm. The 52-week range of $25.36 to $63 shows the stock has moved substantially, with the current price of 62.48 near the top of that range.

AtriCure Inc. (ATRC) is a NASDAQ-listed issuer in the Health Care sector, operating within the Medical/Dental Instruments industry. It has a market capitalization of $3.2B. The company reported revenue of $534.5M for FY 2025, indicating an operating business of meaningful scale.

Revenue grew from $399.2M in FY 2023 to $534.5M in FY 2025, and operating losses narrowed from -$40.0M in FY 2024 to -$9.4M in FY 2025. Per the market data, gross margin is 75%, operating margin is -1.8%, net margin is -2.1%, and ROIC is -1.9%. The Altman Z-Score is 12.08 and the Piotroski F-Score is 8/9, both supportive readings. FY 2025 cash of $167.4M exceeds debt of $61.9M, and the RQD rating reports Debt/Equity of 0.13.

• 🐂 Primary Bull Case: A 12.08 Altman Z-Score, 8/9 Piotroski F-Score, and 0.13 Debt/Equity point to a low-leverage balance sheet with $167.4M in FY 2025 cash. With Fundamental Cash Engine at 10/20 (ROIC -1.9%, FCF yield 1.52%) and Institutional Whale Flow at 17/20, sustained execution supports upside toward the top of the $25.36 – $63.00 52-week range.
• 🐻 Primary Bear Case: Operating margin of -1.8% and ROIC of -1.9% show the business is not yet earning returns on invested capital despite a $3.18B market cap. Investors must weigh current valuation against -1.8% operating margins and a 1.00 macro beta if sector demand softens.

Sector classification is Health Care, Medical/Dental Instruments.

• Key Question #1: Why do EPS, P/E, and EV/EBITDA remain unavailable, and how would these valuation metrics compare to peers?
• Key Question #2: What drove the FY 2025 swing in FCF from $0.7M to $48.3M, and is that cash generation repeatable?
• Key Question #3: How sensitive is ATRC's 75.0% gross margin and equity valuation to Health Care demand cycles and macro interest-rate shifts (Beta 1.00)?